Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline

Boyd, Sara E., Livermore, David and Hooper, David C. (2020) Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrobial Agents and Chemotherapy, 64 (10). ISSN 0066-4804

[img]
Preview
PDF (MBLfinal) - Accepted Version
Download (959kB) | Preview

Abstract

Modern medicine is threatened by the global rise of antibiotic resistance, especially among Gram-negative bacteria. Metallo-β-lactamase (MBL) enzymes are a particular concern and are increasingly disseminated worldwide, though particularly in Asia. Many MBL producers have multiple further drug resistances, leaving few obvious treatment options. Nonetheless, and more encouragingly, MBLs may be less effective agents of carbapenem resistance in vivo, under zinc limitation, than in vitro. Owing to their unique structure and function and their diversity, MBLs pose a particular challenge for drug development. They evade all recently licensed β-lactam-β-lactamase inhibitor combinations, although several stable agents and inhibitor combinations are at various stages in the development pipeline. These potential therapies, along with the epidemiology of producers and current treatment options, are the focus of this review.

Item Type: Article
Uncontrolled Keywords: drug development,metallo-β-lactamase,metalloenzymes,pharmacology,treatment,pharmacology,pharmacology (medical),infectious diseases ,/dk/atira/pure/subjectarea/asjc/3000/3004
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 14 Jul 2020 23:50
Last Modified: 10 Aug 2021 01:18
URI: https://ueaeprints.uea.ac.uk/id/eprint/76048
DOI: 10.1128/AAC.00397-20

Actions (login required)

View Item View Item